Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSVpreF vaccine in adults 60+ years
NCT05035212Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Aug 2021
- Primary completion
- Jan 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 7
01
Overview
A Phase 3 trial of RSVpreF vaccine in respiratory syncytial virus infection (RSV), sponsored by Pfizer. Started Aug 2021; status: active, not recruiting.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05035212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05035212.